Research Lab

Folkman Laboratory

Key Publications

The following represent landmark publications in the study of angiogenesis: 

  • Folkman J. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 1971; 285: 1182-1186.
     
  • Gimbrone MA Jr. Culture of vascular endothelium. Progress in Hemostasis & Thrombosis 1976; 3: 1-28.
     
  • Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 180; 208: 516-518.
     
  • Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M.Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor.Science 1984; 223: 1296-1299.
     
  • Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339 :58-61.
     
  • Ezekowitz A, Mulliken J, Folkman J. Interferon alpha therapy of haemangiomas in newborns and infants. British Journal of Haematology 1991; 79: 67-68.
     
  • Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-557.
     
  • O'Reilly MS. Holmgren L. Shing Y. Chen C. Rosenthal RA. Moses M. Lane WS. Cao Y. Sage EH. Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79 :315-328.
     
  • Boehm T. Folkman J. Browder T. O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390 : 404-407.
     
  • Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Research 1998; 58 :1395-1399.
     
  • Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999; 99: 1726-1732.
     
  • Browder T. Butterfield CE. Kraling BM. Shi B. Marshall B. O'Reilly MS. Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Research 2000; 60: 1878-1886.
     
  • Rohan RM, Fernandez A, Udagawa T, Yuan J, D'Amato RJ. Genetic heterogeneity of angiogenesis in mice. FASEB Journal 2000; 14: 871-876.
  • Achilles EG, Fernandez A, Allred EN, Kisker O, Udagawa T, Beecken WD, Flynn E, Folkman J. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. Journal of the National Cancer Institute 2001: 93: 1075-1081.
     
  • Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proceedings of the National Academy of Sciences USA 2002; 99 :10730-10735.
     
  • Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder JP Jr, Folkman J, Soker S. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Research 2003; 63: 8345-50.
     
  • Abbollhi A, Hahnfeldt P, Maercker C, Grone, HJ, Debus,I, Ansorge W, Folkman J, Hlatky L, Huber PE. Endostatin's antiangiogenic signaling network, Molecular Cell 2004; 13:649-663

To access Dr. Folkman's publications on Pub Med, click here.